Histidine-tryptophan-ketoglutarate for pancreas allograft preservation: The Indiana university experience

J. A. Fridell, Richard Mangus, J. A. Powelson

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Histidine-tryptophan-ketoglutarate solution (HTK) has been scrutinized for use in pancreas transplantation. A recent case series and a United Network for Organ Sharing data base review have suggested an increased incidence of allograft pancreatitis and graft loss with HTK compared to the University of Wisconsin solution (UW). Conversely, a recent randomized, controlled study failed to show any significant difference between HTK and UW for pancreas allograft preservation. This study was a retrospective review of all pancreas transplants performed at Indiana University between 2003 and 2009 comparing preservation with HTK or UW. Data included recipient and donor demographics, 7-day, 90-day and 1-year graft survival, peak 30-day serum amylase and lipase, HbA1c and C-peptide levels. Of the 308 pancreas transplants, 84% used HTK and 16% UW. There were more SPK compared to pancreas after kidney and pancreas transplant alone in the HTK group. Donor and recipient demographics were similar. There was no significant difference in 7-day, 90-day or 1-year graft survival, 30-day peak serum amylase and lipase, HbA1c or C-peptide. No clinically significant difference between HTK and UW for pancreas allograft preservation was identified. Specifically, in the context of low-to-moderate flush volume and short cold ischemia time (≤10 h), no increased incidence of allograft pancreatitis or graft loss was observed.

Original languageEnglish
Pages (from-to)1284-1289
Number of pages6
JournalAmerican Journal of Transplantation
Volume10
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Histidine
Tryptophan
Allografts
Pancreas
Graft Pancreatitis
C-Peptide
Graft Survival
Amylases
Lipase
Transplants
Demography
Cold Ischemia
Pancreas Transplantation
Incidence
Bretschneider cardioplegic solution
Serum
Databases
Kidney

Keywords

  • HTK solution
  • Pancreas transplantation
  • Preservation solutions
  • University of Wisconsin solution

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Histidine-tryptophan-ketoglutarate for pancreas allograft preservation : The Indiana university experience. / Fridell, J. A.; Mangus, Richard; Powelson, J. A.

In: American Journal of Transplantation, Vol. 10, No. 5, 05.2010, p. 1284-1289.

Research output: Contribution to journalArticle

@article{759abcc5fa774632b5a7045e7b295319,
title = "Histidine-tryptophan-ketoglutarate for pancreas allograft preservation: The Indiana university experience",
abstract = "Histidine-tryptophan-ketoglutarate solution (HTK) has been scrutinized for use in pancreas transplantation. A recent case series and a United Network for Organ Sharing data base review have suggested an increased incidence of allograft pancreatitis and graft loss with HTK compared to the University of Wisconsin solution (UW). Conversely, a recent randomized, controlled study failed to show any significant difference between HTK and UW for pancreas allograft preservation. This study was a retrospective review of all pancreas transplants performed at Indiana University between 2003 and 2009 comparing preservation with HTK or UW. Data included recipient and donor demographics, 7-day, 90-day and 1-year graft survival, peak 30-day serum amylase and lipase, HbA1c and C-peptide levels. Of the 308 pancreas transplants, 84{\%} used HTK and 16{\%} UW. There were more SPK compared to pancreas after kidney and pancreas transplant alone in the HTK group. Donor and recipient demographics were similar. There was no significant difference in 7-day, 90-day or 1-year graft survival, 30-day peak serum amylase and lipase, HbA1c or C-peptide. No clinically significant difference between HTK and UW for pancreas allograft preservation was identified. Specifically, in the context of low-to-moderate flush volume and short cold ischemia time (≤10 h), no increased incidence of allograft pancreatitis or graft loss was observed.",
keywords = "HTK solution, Pancreas transplantation, Preservation solutions, University of Wisconsin solution",
author = "Fridell, {J. A.} and Richard Mangus and Powelson, {J. A.}",
year = "2010",
month = "5",
doi = "10.1111/j.1600-6143.2010.03095.x",
language = "English",
volume = "10",
pages = "1284--1289",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Histidine-tryptophan-ketoglutarate for pancreas allograft preservation

T2 - The Indiana university experience

AU - Fridell, J. A.

AU - Mangus, Richard

AU - Powelson, J. A.

PY - 2010/5

Y1 - 2010/5

N2 - Histidine-tryptophan-ketoglutarate solution (HTK) has been scrutinized for use in pancreas transplantation. A recent case series and a United Network for Organ Sharing data base review have suggested an increased incidence of allograft pancreatitis and graft loss with HTK compared to the University of Wisconsin solution (UW). Conversely, a recent randomized, controlled study failed to show any significant difference between HTK and UW for pancreas allograft preservation. This study was a retrospective review of all pancreas transplants performed at Indiana University between 2003 and 2009 comparing preservation with HTK or UW. Data included recipient and donor demographics, 7-day, 90-day and 1-year graft survival, peak 30-day serum amylase and lipase, HbA1c and C-peptide levels. Of the 308 pancreas transplants, 84% used HTK and 16% UW. There were more SPK compared to pancreas after kidney and pancreas transplant alone in the HTK group. Donor and recipient demographics were similar. There was no significant difference in 7-day, 90-day or 1-year graft survival, 30-day peak serum amylase and lipase, HbA1c or C-peptide. No clinically significant difference between HTK and UW for pancreas allograft preservation was identified. Specifically, in the context of low-to-moderate flush volume and short cold ischemia time (≤10 h), no increased incidence of allograft pancreatitis or graft loss was observed.

AB - Histidine-tryptophan-ketoglutarate solution (HTK) has been scrutinized for use in pancreas transplantation. A recent case series and a United Network for Organ Sharing data base review have suggested an increased incidence of allograft pancreatitis and graft loss with HTK compared to the University of Wisconsin solution (UW). Conversely, a recent randomized, controlled study failed to show any significant difference between HTK and UW for pancreas allograft preservation. This study was a retrospective review of all pancreas transplants performed at Indiana University between 2003 and 2009 comparing preservation with HTK or UW. Data included recipient and donor demographics, 7-day, 90-day and 1-year graft survival, peak 30-day serum amylase and lipase, HbA1c and C-peptide levels. Of the 308 pancreas transplants, 84% used HTK and 16% UW. There were more SPK compared to pancreas after kidney and pancreas transplant alone in the HTK group. Donor and recipient demographics were similar. There was no significant difference in 7-day, 90-day or 1-year graft survival, 30-day peak serum amylase and lipase, HbA1c or C-peptide. No clinically significant difference between HTK and UW for pancreas allograft preservation was identified. Specifically, in the context of low-to-moderate flush volume and short cold ischemia time (≤10 h), no increased incidence of allograft pancreatitis or graft loss was observed.

KW - HTK solution

KW - Pancreas transplantation

KW - Preservation solutions

KW - University of Wisconsin solution

UR - http://www.scopus.com/inward/record.url?scp=77951218372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951218372&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2010.03095.x

DO - 10.1111/j.1600-6143.2010.03095.x

M3 - Article

C2 - 20353471

AN - SCOPUS:77951218372

VL - 10

SP - 1284

EP - 1289

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 5

ER -